Literature DB >> 7917913

Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients.

L A Stark1, M J Arends, K M McLaren, E C Benton, H Shahidullah, J A Hunter, C C Bird.   

Abstract

Renal allograft recipients suffer from a markedly increased susceptibility to premalignant and malignant cutaneous lesions. Although various aetiological factors have been implicated, little is known of the associated genetic events. In this study we initially employed immunocytochemical techniques to investigate the prevalence and localisation of accumulated p53 in over 200 cutaneous biopsies (including 56 squamous cell carcinomas) from renal allograft recipients and immunocompetent controls. In renal allograft recipients accumulated p53 was present in 24% of uninvolved skin samples, 14% of viral warts, 41% of premalignant keratoses, 65% of intraepidermal carcinomas and 56% of squamous cell carcinomas [squamous cell carcinoma and intraepidermal carcinoma differed significantly from uninvolved skin (P < 0.005) and viral warts (P < 0.01)]. A similar trend was revealed in immunocompetent patients (an older, chronically sun-exposed population) but with lower prevalence of p53 immunoreactivity: 25% of uninvolved skin samples, 0% of viral warts, 25% of keratoses, 53% of intraepidermal carcinomas and 53% of squamous cell carcinomas. These differences were not statistically significant. Morphologically, p53 immunoreactivity strongly associated with areas of epidermal dysplasia and the abundance of staining correlated positively with the severity of dysplasia. These data suggest that p53 plays a role in skin carcinogenesis and is associated with progression towards the invasive state. No correlation was observed between accumulated p53 and the presence of human papillomavirus (HPV) DNA in any of the lesions. Single-strand conformational polymorphism analysis (exons 5-8) was used to determine the frequency of mutated p53 in 28 malignancies with varying degrees of immunopositivity. p53 mutations were found in 5/9 (56%) malignancies with p53 staining in > 50% of cells, reducing to 1/6 (17%) where 10-50% of cells were positively stained and none where < 10% of cells were stained. These data imply that factors other than p53 gene mutation play a part in accumulation of p53 in skin cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917913      PMCID: PMC2033393          DOI: 10.1038/bjc.1994.367

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  56 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Authors:  S M Bodner; J D Minna; S M Jensen; D D'Amico; D Carbone; T Mitsudomi; J Fedorko; D L Buchhagen; M M Nau; A F Gazdar
Journal:  Oncogene       Date:  1992-04       Impact factor: 9.867

3.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

5.  Effect fixation on T and B lymphocyte surface membrane antigen demonstration in paraffin processed tissue.

Authors:  C S Holgate; P Jackson; K Pollard; D Lunny; C C Bird
Journal:  J Pathol       Date:  1986-08       Impact factor: 7.996

6.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

7.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

8.  Premalignant and malignant skin lesions in renal transplant patients.

Authors:  I Blohmé; O Larkö
Journal:  Transplantation       Date:  1984-02       Impact factor: 4.939

9.  Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours.

Authors:  T Crook; D Wrede; J A Tidy; W P Mason; D J Evans; K H Vousden
Journal:  Lancet       Date:  1992-05-02       Impact factor: 79.321

10.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

Authors:  T Unger; M M Nau; S Segal; J D Minna
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  3 in total

Review 1.  p53 and the pathogenesis of skin cancer.

Authors:  Cara L Benjamin; Honnavara N Ananthaswamy
Journal:  Toxicol Appl Pharmacol       Date:  2006-12-15       Impact factor: 4.219

2.  Human skin carcinoma arising from kidney transplant-derived tumor cells.

Authors:  Laurence Verneuil; Mariana Varna; Philippe Ratajczak; Christophe Leboeuf; Louis-François Plassa; Morad Elbouchtaoui; Pierre Schneider; Wissam Sandid; Celeste Lebbé; Marie-Noelle Peraldi; François Sigaux; Hugues de Thé; Anne Janin
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

3.  High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.

Authors:  M Reuschenbach; T Tran; F Faulstich; W Hartschuh; S Vinokurova; M Kloor; E Krautkrämer; M Zeier; M von Knebel Doeberitz; C Sommerer
Journal:  Br J Cancer       Date:  2011-03-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.